公开(公告)号：US20240067750A1

公开(公告)日：2024-02-29

申请号：US18157312

申请日：2023-01-20

Applicant: NOVARTIS AG

Inventor： Jorg EDER ,  Stefan EWERT ,  Ulrich HASSIEPEN ,  Yasser KHDER ,  Lorenz MAYR ,  Samu MELKKO ,  Nikolaus SCHIERING

IPC: C07K16/36 ,  A61K39/395 ,  A61K45/06 ,  A61P7/02 ,  C07K16/40

CPC classification number: C07K16/36 ,  A61K39/3955 ,  A61K45/06 ,  A61P7/02 ,  C07K16/40 ,  A61K2039/505

Abstract: The present invention relates to monoclonal antibodies and antigen binding fragments thereof that bind to human Factor XI and activated Factor XI (“Factor XIa”), and pharmaceutical compositions and methods of treatment comprising the same.

公开(公告)号：US20200317816A1

公开(公告)日：2020-10-08

申请号：US16840031

申请日：2020-04-03

Applicant: Novartis AG

Inventor： Stefan Ewert ,  Yasser KHDER ,  Alexander KOCH

IPC: C07K16/42 ,  A61K39/395 ,  A61K45/06

Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.

公开(公告)号：US20200231701A1

公开(公告)日：2020-07-23

申请号：US16472641

申请日：2017-12-22

Applicant: Novartis AG

Inventor： Carola FRIEDMAN ,  Yasser KHDER ,  Martin LEFKOWITZ

IPC: C07K16/36 ,  A61P7/02 ,  A61K9/00

Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).

公开(公告)号：US20230002507A1

公开(公告)日：2023-01-05

申请号：US17670270

申请日：2022-02-11

Applicant: Novartis AG

Inventor： Carola FRIEDMAN ,  Yasser KHDER ,  Martin LEFKOWITZ

IPC: C07K16/36 ,  A61P7/02 ,  A61K9/00

Abstract: The present invention relates to methods of preventing, treating or managing, reducing the risk of stroke or thromboembolism in a subject afflicted with end stage renal disease comprising administering a pharmaceutical composition comprising a monoclonal antibody or an antigen binding fragment thereof that bind to human Factor XI and/or activated Factor XI (“Factor XIa”).

公开(公告)号：US20180022825A1

公开(公告)日：2018-01-25

申请号：US15604556

申请日：2017-05-24

Applicant: Novartis AG

Inventor： Stefan EWERT ,  Yasser KHDER ,  Alexander KOCH

IPC: C07K16/42 ,  A61K45/06 ,  A61K39/395

CPC classification number: C07K16/4241 ,  A61K39/39566 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/4208 ,  C07K2317/21 ,  C07K2317/51 ,  C07K2317/515 ,  C07K2317/55 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/76 ,  C07K2317/92

Abstract: The present disclosure relates to reversal agents, which specifically bind to anti-Factor XI and/or anti-Factor XIa antibodies, and reverse one or more anticoagulant effects of the anti-Factor XI and/or anti-Factor XIa antibodies, as well as to methods of use thereof, such as methods for reversing anticoagulant effects of such anti-Factor XI and/or anti-Factor XIa antibodies, and to related methods for managing bleeding or bleeding risks.